Prognostic Factors In Breast Cancer. With Special Reference to Cyclins A, B1, D1 and E, MMP-1 and Decorin

Breast cancer is a highly heterogenous malignancy, which despite of the similar histological type shows different clinical behaviour and response to therapy. Prognostic factors are used to estimate the risk for recurrence and the likelihood of treatment effectiveness. Because breast cancer is one of the most common causes of cancer death in women worldwide, identification of new prognostic markers are needed to develop more specific and targeted therapies. Cancer is caused by uncontrolled cell proliferation. The cell cycle is controlled by specific proteins, which are known as cyclins. They function at important checkpoints by activating cyclin-dependent kinase enzymes. Overexpression of different cyclins has been linked to several cancer types and altered expression of cyclins A, B1, D1 and E has been associated with poor survival. Little is known about the combined expression of cyclins in relation to the tumour grade, breast cancer subtype and other known prognostic factors. In this study cyclins A, B1 and E were shown to correlate with histological grade, Ki-67 and HER2 expression. Overexpression of cyclin D1 correlated with receptor status and non-basal breast cancer suggesting that cyclin D1 might be a marker of good prognosis. Proteolysis in the surrounding tumour stroma is increased during cancer development. Matrix metalloproteinases (MMPs) are proteolytic enzymes that are capable of degrading extracellular matrix proteins. Increased expression and activation of several MMPs have been found in many cancers and MMPs appear to be important regulators of invasion and metastasis. In this study MMP-1 expression was analysed in breast cancer epithelial cells and in cancer associated stromal cells. MMP-1 expression by breast cancer epithelial cells was found to carry an independent prognostic value as did Ki-67 and bcl-2. The results suggest that in addition to stromal cells MMP-1 expression in tumour cells control breast cancer progression. Decorin is a small proteoglycan and an important component of the extracellular matrix. Decorin has been shown to inhibit growth of tumour cells and reduced decorin expression is associated with a poor prognosis in several cancer types. There has been some suspicion wheather different cancer cells express decorin. In this study decorin expression was shown to localize only in the cells of the original stroma, while breast cancer epithelial cells were negative for decorin expression. However, transduction of decorin in decorin-negative human breast cancer cells markedly modulated the growth pattern of these cells. This study provides evidence that targeted decorin transduction to breast cancer cells could be used as a novel adjuvant therapy in breast malignancies.

The Possibilities and Dosimetric Limitations of MLC-Based Intensity-Modulated Radiotherapy Delivery and Optimization Techniques

The use of intensity-modulated radiotherapy (IMRT) has increased extensively in the modern radiotherapy (RT) treatments over the past two decades. Radiation dose distributions can be delivered with higher conformality with IMRT when compared to the conventional 3D-conformal radiotherapy (3D-CRT). Higher conformality and target coverage increases the probability of tumour control and decreases the normal tissue complications. The primary goal of this work is to improve and evaluate the accuracy, efficiency and delivery techniques of RT treatments by using IMRT. This study evaluated the dosimetric limitations and possibilities of IMRT in small (treatments of head-and-neck, prostate and lung cancer) and large volumes (primitive neuroectodermal tumours). The dose coverage of target volumes and the sparing of critical organs were increased with IMRT when compared to 3D-CRT. The developed split field IMRT technique was found to be safe and accurate method in craniospinal irradiations. By using IMRT in simultaneous integrated boosting of biologically defined target volumes of localized prostate cancer high doses were achievable with only small increase in the treatment complexity. Biological plan optimization increased the probability of uncomplicated control on average by 28% when compared to standard IMRT delivery. Unfortunately IMRT carries also some drawbacks. In IMRT the beam modulation is realized by splitting a large radiation field to small apertures. The smaller the beam apertures are the larger the rebuild-up and rebuild-down effects are at the tissue interfaces. The limitations to use IMRT with small apertures in the treatments of small lung tumours were investigated with dosimetric film measurements. The results confirmed that the peripheral doses of the small lung tumours were decreased as the effective field size was decreased. The studied calculation algorithms were not able to model the dose deficiency of the tumours accurately. The use of small sliding window apertures of 2 mm and 4 mm decreased the tumour peripheral dose by 6% when compared to 3D-CRT treatment plan. A direct aperture based optimization (DABO) technique was examined as a solution to decrease the treatment complexity. The DABO IMRT technique was able to achieve treatment plans equivalent with the conventional IMRT fluence based optimization techniques in the concave head-and-neck target volumes. With DABO the effective field sizes were increased and the number of MUs was reduced with a factor of two. The optimality of a treatment plan and the therapeutic ratio can be further enhanced by using dose painting based on regional radiosensitivities imaged with functional imaging methods.

ERBB4 mutations in cancer and amyotrophic lateral sclerosis

ErbB receptor tyrosine kinases, epidermal growth factor receptor (EGFR, also known as ErbB1), ErbB2 (HER2 or NEU), ErbB3 (HER3), and ErbB4 (HER4), transduce signals borne by extracellular ligands into central cellular responses such as proliferation, survival, differentiation, and apoptosis. Mutations in ERBB genes are frequently detected in human malignant diseases of epithelial and neural origin, making ErbB receptors important drug targets. Targeting EGFR and ErbB2 has been successful in eg. lung and breast cancer, respectively, and mutations in these genes can be used to select patients that are responsive to the targeted treatment. Although somatic ERBB4 mutations have been found in many high-incidence cancers such as melanoma, lung cancer, and colorectal cancer and germ-line ERBB4 mutations have been linked to neuronal disorders and cancer, ErbB4 has generally been neglected as a potential drug target. Thus, the consequences of ERBB4 mutations on ErbB4 biology are largely unknown. This thesis aimed to elucidate the functional consequences and assess the clinical significance of somatic and germ-line ERBB4 mutations in the context of cancer and amyotrophic lateral sclerosis. The results of this study indicated that cancer-associated ERBB4 mutations can promote aberrant ErbB4 function by activating the receptor or inducing qualitative changes in ErbB4 signaling. ERBB4 mutations increased survival or decreased differentiation in vitro, suggesting that ERBB4 mutations can be oncogenic. Importantly, the potentially oncogenic mutations were located in various subdomains in ErbB4, possibly providing explanation for the characteristic scattered pattern of mutations in ERBB4. This study also demonstrated that hereditary variation in ERBB4 gene can have a significant effect on the prognosis of breast cancer. In addition, it was shown that hereditary or de novo germ-line ERBB4 mutations that predispose to amyotrophic lateral sclerosis inhibit ErbB4 activity. Together, these results suggest that ErbB4 should be considered as a novel drug target in cancer and amyotrophic lateral sclerosis.

Asbestin tunnistaminen keinonenällä

Asbesti on yleisnimike kuitumaisille silikaattimineraaleille. Sillä on monia hyviä ominaisuuksia. Siksi sitä on käytetty useisiin eri käyttötarkoituksiin jo yli 4 000 vuoden ajan. Sisäänhengitettynä asbesti aiheuttaa kuitenkin vakavia terveyshaittoja, mm. asbestoosia, keuhkosyöpää ja mesotelioomaa. Vuosina 1918-1988 Suomessa käytettiin asbestia 300 000 tonnia. Yleisintä käyttö oli 1960-70-lukujen vaihteessa. Sairauksien viive altistumisesta on 10-40 vuotta. Sairauksien esiintyminen onkin nyt suurimmillaan. Suurin osa sairauksista on hyvänlaatuisia keuhkopussin paksuuntumia eli plakkeja. Vuosittain asbestin aiheuttamiin sairauksiin, etupäässä syöpiin, kuolee Suomessa noin 100 ihmistä. Yhteensä altistuneita arvellaan olevan 250 000. Heistä elossa on noin 50 000. Vaarallisuutensa vuoksi asbestin käyttö on useissa maissa kielletty, mutta maailmalla sitä käytetään edelleen suuria määriä. Suomessa asbestin käyttöä rajoitettiin jo 1970-luvulla. Pieniä poikkeuksia lukuun ottamatta täyskielto tuli voimaan 1.1.1994. Suomessa asbestia esiintyy edelleen vanhoissa rakennuksissa. Asbestipurkutyö on luvanvaraista. Asbestitöissä on huolehdittava siitä, että kukaan ei altistu asbestille. Asbestipitoisen materiaalin tunnistaminen silmämääräisesti on vaikeaa. Materiaali luokitellaan asbestipitoiseksi, jos siinä on asbestia yli 1 painoprosenttia tai jos sitä voidaan pölyävyytensä takia pitää vaarallisena. Asbestipitoisen materiaalin kartoituksessa voidaan käyttää rakennussuunnitelmia, vanhoja asiakirjoja kuten urakoitsijan laskuja sekä tuntemusta rakennusajan yleisistä rakennustavoista. Varmuus saadaan kuitenkin vain tutkimalla materiaali esimerkiksi laboratoriokokeissa. Tässä diplomityössä on pyritty selvittämään, voidaanko asbesti tunnistaa ChemPro 100 -keinonenällä. Laite perustuu ioniliikkuvuusspektrometriaan eli eri yhdisteiden erilaiseen liikkuvuuteen kaasumaisessa väliaineessa. Menetelmä on nopea ja yksinkertainen. Tutkimusta varten hankittiin asbestipitoisia materiaaleja, joista saatuja tuloksia vertailtiin toisiinsa. Nykyiset asbestintunnistusmenetelmät ovat monimutkaisia ja hitaita. Jos keinonenä pystyttäisiin kouluttamaan tunnistamaan asbestimateriaali, helpottaisi se asbestikartoituksen tekemistä.